The Pharma Letter1h
ALK Abello licenses rights to neffy from ARS Pharma
Danish allergy immunotherapy specialist ALK Abello has entered into a strategic license agreement with US-based ARS ...
The Pharma Letter1h
BRIEF—Eisai updates Leqembi outlook
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi ...
The Pharma Letter2h
Swedish life science strategy needs to be fleshed out
According to the Swedish pharma trade group Lif, it is positive that, in the updated life science strategy, the government expresses an ambition for Sweden to become more attractive for research ...
The Pharma Letter2h
NMPA cooperation with Danish Medicines Agency
Li Li, Commissioner of China's National Medical Products Administration (NMPA), and Mette Aaboe Hansen, interim director ...
The Pharma Letter13h
GSK still yielding more than 4%, notes Morningstar
In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...
The Pharma Letter13h
Growing emphasis on disease-modifying therapies in Parkinson’s
The Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective ...